Overview: Inv 16 Quantitative MRD TestIntroduction: The Inv 16 Quantitative MRD Test quantifies inv(16) gene rearrangement to monitor acute myeloid leukemia (AML) treatment, preventing relapse. Following 2023 NCCN guidelines, it uses polymerase chain reaction (PCR) for high sensitivity, supporting cancer screening. This test is critical for assessing minimal residual disease (MRD), guiding treatment adjustments, and improving outcomes in molecular pathology for AML patients.
Other Names: Inv 16 Quant PCR Assay, AML MRD Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Quantitative MRD testing for inv(16) emerged in the 2000s with AML research. PCR-based methods improved sensitivity for relapse monitoring.
Purpose: Quantifies inv(16) gene rearrangement to monitor AML treatment, guides therapy, and prevents relapse.
Test Parameters: 1. Inv 16 Gene Rearrangement (Quantitative)
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva. Report history of AML treatment, fatigue, or bleeding.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document AML history, chemotherapy, fatigue, or bleeding. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, relapse monitoring, and risks of blood or bone marrow collection.
Procedural Considerations: Uses quantitative PCR to measure inv(16) levels in whole blood, bone marrow, or saliva. Results are available in 3-5 days, supporting treatment decisions. Performed in laboratories, often for AML MRD monitoring.
Factors Affecting Result Accuracy: Improper sample storage or contamination can affect results. Low DNA yield may reduce sensitivity.
Clinical Significance: Detectable inv(16) levels indicate residual AML, guiding intensified therapy or transplant. Undetectable levels suggest remission, supporting continued monitoring.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Qualitative inv(16) PCR, flow cytometry, or bone marrow biopsy to monitor AML.
Test Limitations: Sensitivity depends on sample quality; clinical correlation is needed. Rare variants may not be quantified.
References: NCCN AML Guidelines, 2023; Blood, Döhner H, 2022.
